Verrica Pharmaceuticals Inc. (VRCA) — SEC Financial Statements & Analysis

Verrica Pharmaceuticals Inc. (VRCA) is a pharmaceutical preparations company, incorporated in DE. Verrica Pharmaceuticals Inc. trades on Nasdaq as: VRCA. Verrica Pharmaceuticals Inc. (VRCA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Verrica Pharmaceuticals Inc. carries a market cap of $130.39M, a P/E ratio of -4.18x, a P/B ratio of 30.27x, a P/S ratio of 4.30x, an enterprise value of $120.32M, and an EV/EBITDA multiple of -4.25x. On profitability, it posts a gross margin of 162.19%, an operating margin of -93.59%, a net margin of -102.84%, a Return on Equity (ROE) of 473.29%, a Return on Assets (ROA) of -83.02%, and a Return on Invested Capital (ROIC) of -755.30%. Per share, it reports EPS of $-1.46, diluted EPS of $-1.46, free cash flow per share of $-0.63, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 106.21% year-over-year, net income growth of -35.84% year-over-year, and EPS growth of -71.43% year-over-year. On the balance sheet, it maintains a current ratio of 1.45x, a quick ratio of 1.22x, working capital of $10.20M, a debt-to-equity ratio of 7.36x, a debt ratio of 0.88, an interest coverage ratio of -7.60x, free cash flow of $-13.35M (TTM), and net debt of $-10.07M. Figures sourced from SEC EDGAR.

Market Cap

$130.39M

P/E TTM

-4.18x

EPS TTM

$-1.46

P/B TTM

30.27x

ROE TTM

473.29%

ROA TTM

-83.02%

Debt To Equity

7.36x

Free Cash Flow TTM

$-13.35M

Net Revenue TTM Growth 1Y

106.21%

Data as of 2026-06-30 · Source: SEC EDGAR